Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
about
Challenging Standard-of-Care Paradigms in the Precision Oncology Era.Management of recurrent or metastatic thyroid cancer.Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.Meta-analysis of microarray datasets identify several chromosome segregation-related cancer/testis genes potentially contributing to anaplastic thyroid carcinomaNavigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond
P2860
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Dabrafenib and Trametinib Trea ...... ant Anaplastic Thyroid Cancer.
@en
Dabrafenib and Trametinib Trea ...... ant Anaplastic Thyroid Cancer.
@nl
type
label
Dabrafenib and Trametinib Trea ...... ant Anaplastic Thyroid Cancer.
@en
Dabrafenib and Trametinib Trea ...... ant Anaplastic Thyroid Cancer.
@nl
prefLabel
Dabrafenib and Trametinib Trea ...... ant Anaplastic Thyroid Cancer.
@en
Dabrafenib and Trametinib Trea ...... ant Anaplastic Thyroid Cancer.
@nl
P2093
P2860
P356
P1476
Dabrafenib and Trametinib Trea ...... ant Anaplastic Thyroid Cancer.
@en
P2093
Bhumsuk Keam
Bijoyesh Mookerjee
Christoph Zielinski
Dazhe Wang
Fatima Rangwala
Gladys Urbanowitz
Jae Yong Cho
Jan H M Schellens
Jean Charles Soria
Maria E Cabanillas
P2860
P356
10.1200/JCO.2017.73.6785
P407
P577
2017-10-26T00:00:00Z